Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 24, Pages 6210
Publisher
MDPI AG
Online
2021-12-10
DOI
10.3390/cancers13246210
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics
- (2021) Laura Mezquita et al. EUROPEAN JOURNAL OF CANCER
- Clinical decision support algorithm based on machine learning to assess the clinical response to anti–programmed death-1 therapy in patients with non–small-cell lung cancer
- (2021) Beung-Chul Ahn et al. EUROPEAN JOURNAL OF CANCER
- Impact of Performance Status on Response and Survival Among Patients Receiving Checkpoint Inhibitors for Advanced Solid Tumors
- (2021) Mridula Krishnan et al. JCO Oncology Practice
- Calculating the sample size required for developing a clinical prediction model
- (2020) Richard D Riley et al. BMJ-British Medical Journal
- An Enhanced Prognostic Score for Overall Survival of Patients with Cancer Derived from a large Real World Cohort
- (2020) T. Becker et al. ANNALS OF ONCOLOGY
- Artificial Intelligence and Mechanistic Modeling for Clinical Decision Making in Oncology
- (2020) Sebastien Benzekry CLINICAL PHARMACOLOGY & THERAPEUTICS
- ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—A systematic review and meta-analysis of real world data
- (2020) Filippo G. Dall’Olio et al. LUNG CANCER
- LBA53 Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients (pts) treated with PD1/L1 immune checkpoint inhibitors (ICIs): A first analysis of the PIONeeR study
- (2020) F. Barlesi et al. ANNALS OF ONCOLOGY
- Metabolomics to Assess Response to Immune Checkpoint Inhibitors in Patients with Non-Small-Cell Lung Cancer
- (2020) Veronica Ghini et al. Cancers
- Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors
- (2019) Léa Berland et al. Journal of Thoracic Disease
- Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
- (2019) Arnaud Jeanson et al. Journal of Thoracic Oncology
- Predicting Response to Cancer Immunotherapy using Non-invasive Radiomic Biomarkers
- (2019) S Trebeschi et al. ANNALS OF ONCOLOGY
- Machine learning-based predictors for immune checkpoint inhibitor therapy of non-small-cell lung cancer
- (2019) M Wiesweg et al. ANNALS OF ONCOLOGY
- Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
- (2019) J Mazières et al. ANNALS OF ONCOLOGY
- Peripheral Blood Markers Identify Risk of Immune‐Related Toxicity in Advanced Non‐Small Cell Lung Cancer Treated with Immune‐Checkpoint Inhibitors
- (2019) Alberto Pavan et al. ONCOLOGIST
- Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction
- (2019) David M. Kurtz et al. CELL
- A systematic review shows no performance benefit of machine learning over logistic regression for clinical prediction models
- (2019) Evangelia Christodoulou et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Metabolomic adaptations and correlates of survival to immune checkpoint blockade
- (2019) Haoxin Li et al. Nature Communications
- Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC
- (2018) B. Melosky et al. CANCER TREATMENT REVIEWS
- A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics
- (2018) Laurent Claret et al. CLINICAL CANCER RESEARCH
- Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma
- (2018) Yiwei Liu et al. Clinical Lung Cancer
- Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
- (2018) Hira Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer
- (2018) Laura Mezquita et al. JAMA Oncology
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study
- (2018) Roger Sun et al. LANCET ONCOLOGY
- Vulnerabilities of radiomic signature development: The need for safeguards
- (2018) Mattea L. Welch et al. RADIOTHERAPY AND ONCOLOGY
- Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
- (2017) Stefan Diem et al. LUNG CANCER
- Is the derived neutrophil to lymphocyte ratio (dNLR) an independent prognostic marker in patients with metastatic colorectal cancer (mCRC)? Analysis of the CO.17 and CO.20 studies
- (2016) C.I. Diakos et al. ANNALS OF ONCOLOGY
- Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
- (2016) P. F. Ferrucci et al. ANNALS OF ONCOLOGY
- Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy
- (2016) R. Serre et al. CANCER RESEARCH
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients
- (2016) Xiaobin Gu et al. Scientific Reports
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- (2013) Michael S. Lawrence et al. NATURE
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer
- (2012) M J Proctor et al. BRITISH JOURNAL OF CANCER
- The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
- (2011) M J M Gooden et al. BRITISH JOURNAL OF CANCER
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started